The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease

AimTo assess safety of COVID-19 vaccination in paediatric patients with immune-mediated inflammatory disease (IMID).MethodsSubjects of 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine to assess side effects within 1 week of vaccination, current medications and COVID-19 testing after vaccination. Charts were reviewed for COVID-19 polymerase chain reaction and IgG response to SARS-CoV-2 spike protein results and for disease flare during the study period.ResultsAmong 190 enrolled subjects, 71% were female, with median age 17 (range 6-21) years. The most common diagnosis was juvenile idiopathic arthritis/rheumatoid arthritis (55%). 78% of subjects were taking immunosuppressive medication. At least one side effect was reported in 65% of subjects after any dose of the vaccine; with side effects in 38%, 53% and 55% of subjects after the first, second and third vaccine doses, respectively. The most common side effects were injection site pain (59%), fatigue (54%) and headache (39%). No anaphylaxis or myocarditis was reported. Three subjects (2%) experienced disease flare.ConclusionIn our cohort of paediatric patients with IMID, observed side effects were found to be mild and disease flare rates were found to be low following COVID-19 vaccination.

Automated summary

This study aimed to assess the safety of COVID-19 vaccination in paediatric patients with immune-mediated inflammatory disease (IMID). The results showed that the observed side effects were mild and disease flare rates were low following COVID-19 vaccination in this cohort.